title: Rapid killing of M. leprae by moxifloxacin in two patients with lepromatous leprosy.
abstract: BACKGROUND
  Previously we reported a 2-month clinical trial of moxifloxacin therapy in eight patients with MB leprosy (7 LL and 1 BL), finding both rapid killing of M. leprae and clinical improvement, without serious side effects or toxicities. Here we report the outcomes in two patients treated with moxifloxacin.
  
  
  METHODS
  Two previously untreated LL patients were treated with a single 400 mg dose of moxifloxacin, no therapy for 7 days and then daily 400 mg moxifloxacin for 48 days. Clinical response, viability of M. leprae in the skin, and side effects/toxicities were carefully monitored.
  
  
  RESULTS
  In both patients a single dose of moxifloxacin resulted in significant killing of M. leprae (P < 0.001%). In both patients no viable M. leprae were found after 15 doses of moxifloxacin. Improvement in skin lesions occurred again remarkably rapidly and no untoward effects were noted.
  
  
  CONCLUSIONS
  Loss of viable M. leprae was quite rapid, similar to that found previously only for rifampicin, patients improved rapidly, and moxifloxacin was well tolerated.
authors.affiliation: Leonard Wood Memorial Center for Leprosy Research, Cebu, Philippines.
authors.forename: Fe Eleanor F
authors.initials: FE
authors.lastname: Pardillo
authors.forename: Jasmin
authors.initials: J
authors.lastname: Burgos
authors.forename: Tranquilino T
authors.initials: TT
authors.lastname: Fajardo
authors.forename: Eduardo
authors.initials: E
authors.lastname: Dela Crux
authors.forename: Rodolfo M
authors.initials: RM
authors.lastname: Abalos
authors.forename: Rose Maria D
authors.initials: RM
authors.lastname: Paredes
authors.forename: Cora Evelyn S
authors.initials: CE
authors.lastname: Andaya
authors.forename: Robert H
authors.initials: RH
authors.lastname: Gelber
mesh_terms: D000328:Adult; D001372:Aza Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D024841:Fluoroquinolones; D006801:Humans; D007917:Leprostatic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D015440:Leprosy, Lepromatous / Q000188:drug therapy* / Q000382:microbiology; D008297:Male; D050296:Microbial Viability / Q000187:drug effects*; D008875:Middle Aged; D000077266:Moxifloxacin; D009166:Mycobacterium leprae / Q000187:drug effects* / Q000302:isolation & purification; D011804:Quinolines / Q000008:administration & dosage / Q000627:therapeutic use*; D012867:Skin / Q000382:microbiology / Q000473:pathology; D016896:Treatment Outcome
chemical_list: D001372:Aza Compounds; D024841:Fluoroquinolones; D007917:Leprostatic Agents; D011804:Quinolines; D000077266:Moxifloxacin